{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:19:45Z","timestamp":1792271985659,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM109025"],"award-info":[{"award-number":["P20GM109025"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["U01NS093334"],"award-info":[{"award-number":["U01NS093334"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG053798"],"award-info":[{"award-number":["R01AG053798"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Drug development for neurodegenerative disorders (NDDs) is a long, complex, and expensive enterprise. Methods to optimize drug development for NDDs are needed. Basket trials have been widely used in oncology and have been promoted by the Food and Drug Administration as a means of enhancing the efficiency of drug development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>We reviewed clinical trials for NDDs registered on clinicaltrials.gov in the past 10 years. We identified 59 basket trials assessing the impact of treatment on more than one NDD in the trial. Forty-one of the trials were for 25 agents addressing symptoms of NDD such as motor impairment, hypotension, or psychosis. Eighteen of the trials assessed 14 disease-modifying therapies; the principal targets were mitochondrial function, tau biology, or alpha-synuclein aggregation. Basket trials are most common in phase 2 but have been conducted in phase 1, phase 3, and phase 4. The duration and size of the basket trials are highly variable depending on their developmental phase and the intent of the trial. Parkinson\u2019s disease was the most common disorder included in basket trials of symptomatic agents, and Alzheimer\u2019s disease was the most common disorder included in basket trials of disease-modifying therapies. Most of the basket trials of symptomatic agents were sponsored by pharmaceutical companies (29 of 41 trials); similarly, most of the basket trials investigating DMTs in basket trials were sponsored by the biopharmaceutical industry (11\/17 trials).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Basket trials may increase drug development efficiency by reducing redundancy in trial implementation, enhancing recruitment, sharing placebo groups, and using biomarkers relevant to the mechanism of action of the treatment across NDDs. There have been relatively few basket trials including multiple NDDs in the same trial conducted over the past 10 years. The use of the basket trial strategy may represent an opportunity to increase the efficiency of development programs for agents to treat NDDs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-022-01015-6","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T07:03:04Z","timestamp":1653462184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["The role of basket trials in drug development for neurodegenerative disorders"],"prefix":"10.1186","volume":"14","author":[{"given":"Jeffrey","family":"Cummings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Kamboj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Fonseca","family":"Cacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"key":"1015_CR1","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.2147\/CIA.S264688","volume":"15","author":"P Maresova","year":"2020","unstructured":"Maresova P, Hruska J, Klimova B, Barakovic S, Krejcar O. Activities of daily living and associated costs in the most widespread neurodegenerative diseases: a systematic review. Clin Interv Aging. 2020;15:1841\u201362.","journal-title":"Clin Interv Aging."},{"issue":"5","key":"1015_CR2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1242\/dmm.030205","volume":"10","author":"AD Gitler","year":"2017","unstructured":"Gitler AD, Dhillon P, Shorter J. Neurodegenerative disease: models, mechanisms, and a new hope. Dis Model Mech. 2017;10(5):499\u2013502.","journal-title":"Dis Model Mech."},{"issue":"9","key":"1015_CR3","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1289\/ehp.7567","volume":"113","author":"RC Brown","year":"2005","unstructured":"Brown RC, Lockwood AH, Sonawane BR. Neurodegenerative diseases: an overview of environmental risk factors. Environ Health Perspect. 2005;113(9):1250\u20136.","journal-title":"Environ Health Perspect."},{"issue":"9503","key":"1015_CR4","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/S0140-6736(05)67889-0","volume":"366","author":"CP Ferri","year":"2005","unstructured":"Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112\u20137.","journal-title":"Lancet."},{"issue":"1","key":"1015_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2016.07.150","volume":"13","author":"A Wimo","year":"2017","unstructured":"Wimo A, Guerchet M, Ali GC, Wu YT, Prina AM, Winblad B, et al. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement. 2017;13(1):1\u20137.","journal-title":"Alzheimers Dement."},{"key":"1015_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/nyas.12417","volume":"1313","author":"TJ Scott","year":"2014","unstructured":"Scott TJ, O'Connor AC, Link AN, Beaulieu TJ. Economic analysis of opportunities to accelerate Alzheimer\u2019s disease research and development. Ann N Y Acad Sci. 2014;1313:17\u201334.","journal-title":"Ann N Y Acad Sci."},{"key":"1015_CR7","first-page":"5380346","volume":"2020","author":"AE Oxford","year":"2020","unstructured":"Oxford AE, Stewart ES, Rohn TT. Clinical trials in Alzheimer\u2019s disease: a hurdle in the path of remedy. Int J Alzheimers Dis. 2020;2020:5380346.","journal-title":"Int J Alzheimers Dis."},{"issue":"3","key":"1015_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/14737175.2019.1581610","volume":"19","author":"H Yoshino","year":"2019","unstructured":"Yoshino H. Edaravone for the treatment of amyotrophic lateral sclerosis. Expert Rev Neurother. 2019;19(3):185\u201393.","journal-title":"Expert Rev Neurother."},{"issue":"1","key":"1015_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13195-021-00838-z","volume":"13","author":"J Cummings","year":"2021","unstructured":"Cummings J, Aisen P, Lemere C, Atri A, Sabbagh M, Salloway S. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimers Res Ther. 2021;13(1):98.","journal-title":"Alzheimers Res Ther."},{"issue":"1","key":"1015_CR10","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1186\/s13063-019-3664-1","volume":"20","author":"JJH Park","year":"2019","unstructured":"Park JJH, Siden E, Zoratti MJ, Dron L, Harari O, Singer J, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials. 2019;20(1):572.","journal-title":"Trials."},{"key":"1015_CR11","doi-asserted-by":"crossref","unstructured":"Lu CC, Li XN, Broglio K, Bycott P, Jiang Q, Li X, et al. Practical considerations and recommendations for master protocol framework: basket, umbrella and platform trials. Ther Innov Regul Sci. 2021;55:1145\u201354.","DOI":"10.1007\/s43441-021-00315-7"},{"key":"1015_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1146\/annurev-med-062016-050343","volume":"69","author":"JJ Tao","year":"2018","unstructured":"Tao JJ, Schram AM, Hyman DM. Basket studies: redefining clinical trials in the era of genome-driven oncology. Annu Rev Med. 2018;69:319\u201331.","journal-title":"Annu Rev Med."},{"key":"1015_CR13","unstructured":"Food and Drug Administration. Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry. Draft guidance. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Oncology Center of Excellence (OCE). September 2018."},{"key":"1015_CR14","unstructured":"Clinicaltrials.gov [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/."},{"key":"1015_CR15","unstructured":"Food and Drug Administration. Regulations (42 CFR Part 11)."},{"key":"1015_CR16","unstructured":"NDDDrugMatcher [Internet]. GitHub, Inc. 2021. Available from: https:\/\/github.com\/SniperJF\/NDDDrugMatcher."},{"key":"1015_CR17","doi-asserted-by":"crossref","unstructured":"Fonseca Cacho JRF, Taghva K. The state of reproducible research in computer science. In: Latifi S, editor. In 17th International Conference on Information Technology\u2013New Generations (INTG 2020) Advances in Intelligent Systems and Computing. 1134: Springer, Cham; 2020.","DOI":"10.1007\/978-3-030-43020-7_68"},{"key":"1015_CR18","unstructured":"National Institute on Aging, Alzheimer\u2019s Association. International Alzheimer\u2019s and Related Dementia Research Portfolio; Available from: https:\/\/iadrp.nia.nih.gov\/about\/cadro. Accessed 01\/01\/2021"},{"issue":"2","key":"1015_CR19","first-page":"109","volume":"4","author":"J Cummings","year":"2017","unstructured":"Cummings J, Fox N. Defining disease modifying therapy for Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2017;4(2):109\u201315.","journal-title":"J Prev Alzheimers Dis."},{"issue":"9","key":"1015_CR20","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1017\/S1041610216000582","volume":"28","author":"MB Deutsch","year":"2016","unstructured":"Deutsch MB, Liang LJ, Jimenez EE, Mather MJ, Mendez MF. Are we comparing frontotemporal dementia and Alzheimer disease patients with the right measures? Int Psychogeriatr. 2016;28(9):1481\u20135.","journal-title":"Int Psychogeriatr."},{"issue":"7","key":"1015_CR21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2165\/00002512-200118070-00003","volume":"18","author":"JM Senard","year":"2001","unstructured":"Senard JM, Brefel-Courbon C, Rascol O, Montastruc JL. Orthostatic hypotension in patients with Parkinson\u2019s disease: pathophysiology and management. Drugs Aging. 2001;18(7):495\u2013505.","journal-title":"Drugs Aging."},{"issue":"5","key":"1015_CR22","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/ana.20828","volume":"59","author":"HS Panitch","year":"2006","unstructured":"Panitch HS, Thisted RA, Smith RA, Wynn DR, Wymer JP, Achiron A, et al. Randomized, controlled trial of dextromethorphan\/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol. 2006;59(5):780\u20137.","journal-title":"Ann Neurol."},{"issue":"8","key":"1015_CR23","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1212\/01.WNL.0000142042.50528.2F","volume":"63","author":"BR Brooks","year":"2004","unstructured":"Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg JE, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan\/quinidine: a randomized trial. Neurology. 2004;63(8):1364\u201370.","journal-title":"Neurology."},{"issue":"5","key":"1015_CR24","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/ana.22093","volume":"68","author":"EP Pioro","year":"2010","unstructured":"Pioro EP, Brooks BR, Cummings J, Schiffer R, Thisted RA, Wynn D, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68(5):693\u2013702.","journal-title":"Ann Neurol."},{"issue":"4","key":"1015_CR25","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1159\/000008243","volume":"44","author":"M Farlow","year":"2000","unstructured":"Farlow M, Anand R, Messina J Jr, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer\u2019s disease. Eur Neurol. 2000;44(4):236\u201341.","journal-title":"Eur Neurol."},{"issue":"24","key":"1015_CR26","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa041470","volume":"351","author":"M Emre","year":"2004","unstructured":"Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson\u2019s disease. N Engl J Med. 2004;351(24):2509\u201318.","journal-title":"N Engl J Med."},{"issue":"2","key":"1015_CR27","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3233\/JAD-170650","volume":"61","author":"A Dodich","year":"2018","unstructured":"Dodich A, Cerami C, Cappa SF, Marcone A, Golzi V, Zamboni M, et al. Combined socio-behavioral evaluation improves the differential diagnosis between the behavioral variant of frontotemporal dementia and Alzheimer\u2019s disease: in search of neuropsychological markers. J Alzheimers Dis. 2018;61(2):761\u201372.","journal-title":"J Alzheimers Dis."},{"key":"1015_CR28","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"W Guy","year":"1976","unstructured":"Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville: US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976."},{"issue":"7","key":"1015_CR29","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28\u201337.","journal-title":"Psychiatry (Edgmont)."},{"issue":"9","key":"1015_CR30","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJM199403033300901","volume":"330","author":"G Bensimon","year":"1994","unstructured":"Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole Study Group. N Engl J Med. 1994;330(9):585\u201391.","journal-title":"N Engl J Med."},{"issue":"2","key":"1015_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1001\/jamaneurol.2019.3812","volume":"77","author":"RM Tsai","year":"2020","unstructured":"Tsai RM, Miller Z, Koestler M, Rojas JC, Ljubenkov PA, Rosen HJ, et al. Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with Alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: a randomized clinical trial. JAMA Neurol. 2020;77(2):215\u201324.","journal-title":"JAMA Neurol."},{"key":"1015_CR32","doi-asserted-by":"crossref","unstructured":"Tariot P, Cummings J, Soto-Martin ME, Ballard C, Erten-Lyons D, Sultzer D, et al. Trial of pimavanserin in dementia-related psychosis. New Engl J Med. 2021; In Press.","DOI":"10.1056\/NEJMoa2034634"},{"key":"1015_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.106149","volume":"98","author":"V Bunn","year":"2020","unstructured":"Bunn V, Liu R, Lin J, Lin J. Flexible Bayesian subgroup analysis in early and confirmatory trials. Contemp Clin Trials. 2020;98:106149.","journal-title":"Contemp Clin Trials."},{"issue":"2","key":"1015_CR34","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/bimj.201800404","volume":"62","author":"K Fujikawa","year":"2020","unstructured":"Fujikawa K, Teramukai S, Yokota I, Daimon T. A Bayesian basket trial design that borrows information across strata based on the similarity between the posterior distributions of the response probability. Biom J. 2020;62(2):330\u20138.","journal-title":"Biom J."},{"issue":"1","key":"1015_CR35","first-page":"1","volume":"8","author":"YM Kuo","year":"2019","unstructured":"Kuo YM, Nwankwo EI, Nussbaum RL, Rogers J, Maccecchini ML. Translational inhibition of alpha-synuclein by Posiphen normalizes distal colon motility in transgenic Parkinson mice. Am J Neurodegener Dis. 2019;8(1):1\u201315.","journal-title":"Am J Neurodegener Dis."},{"issue":"9","key":"1015_CR36","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1136\/jnnp-2012-302589","volume":"83","author":"ML Maccecchini","year":"2012","unstructured":"Maccecchini ML, Chang MY, Pan C, John V, Zetterberg H, Greig NH. Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-beta peptide and tau levels: target engagement, tolerability and pharmacokinetics in humans. J Neurol Neurosurg Psychiatry. 2012;83(9):894\u2013902.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"11","key":"1015_CR37","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJMsa1409364","volume":"372","author":"ML Anderson","year":"2015","unstructured":"Anderson ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM. Compliance with results reporting at ClinicalTrials.gov. N Engl J Med. 2015;372(11):1031\u20139.","journal-title":"N Engl J Med."},{"issue":"10221","key":"1015_CR38","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0140-6736(19)33220-9","volume":"395","author":"NJ DeVito","year":"2020","unstructured":"DeVito NJ, Bacon S, Goldacre B. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. Lancet. 2020;395(10221):361\u20139.","journal-title":"Lancet."}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01015-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-022-01015-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01015-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T19:03:08Z","timestamp":1653505388000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-022-01015-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1015"],"URL":"https:\/\/doi.org\/10.1186\/s13195-022-01015-6","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,25]]},"assertion":[{"value":"23 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable; all data are from a public database that has no participant-level data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors give consent for publication","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JC has provided consultation to Acadia, Alkahest, AlphaCognition, AriBio, Biogen, Cassava, Cortexyme, Diadem, EIP Pharma, Eisai, GemVax, Genentech, Green Valley, Grifols, Janssen, Lilly, LSP, Merck, NervGen, Novo Nordisk, Oligomerix, Ono, Otsuka, PRODEO, Prothena, ReMYND, Resverlogix, Roche, Signant Health, Suven, and United Neuroscience pharmaceutical, assessment, and investment companies. JC is supported by NIGMS grant P20GM109025, NINDS grant U01NS093334, NIA grant R01AG053798, NIA grant P20AG068053, NIA grant P30AG072959,\u00a0NIA grant R35AG71476, Alzheimer\u2019s Disease Drug Discovery Foundation (ADDF), Ted and Maria Quirk Endowment,\u00a0and the Joy Chambers-Grundy Endowment.AM, JF-C, and SK have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}